Genetic mutation screen in early non-small-cell lung cancer (NSCLC) specimens

Clinical Lung Cancer

Volumn 15, Issue 2, 2014, Pages 159-165

  Bar, Jair ^a   Damianovich, Maya ^a   Hout Siloni, Goni ^a   Dar, Erel ^a   Cohen, Yoram ^a   Perelman, Marina ^a   Ben Nun, Alon ^a   Simansky, David ^a   Yellin, Alon ^a   Urban, Damien ^b   Onn, Amir ^a  

^a SHEBA MEDICAL CENTER   (Israel)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

Co mutation; FFPE; Sequenom; Transitions; Transversion

Indexed keywords

EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN;

ADENOCARCINOMA; CANCER STAGING; CLINICAL TRIAL; FOLLOW UP; GENETIC SCREENING; GENETICS; HUMAN; LUNG TUMOR; MASS SPECTROMETRY; MORTALITY; MUTATION; NON SMALL CELL LUNG CANCER; PATHOLOGY; POLYMERASE CHAIN REACTION; PROGNOSIS; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE;

ADENOCARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FOLLOW-UP STUDIES; GENETIC TESTING; HUMANS; LUNG NEOPLASMS; MUTATION; NEOPLASM STAGING; PHOSPHATIDYLINOSITOL 3-KINASES; POLYMERASE CHAIN REACTION; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SURVIVAL RATE;

EID: 84894072604     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2013.11.005     Document Type: Article

References (34)

1. A. Jemal, F. Bray, and M.M. Center et al. Global cancer statistics CA Cancer J Clin 61 2011 69 90
2. J.G. Paez, P.A. Janne, and J.C. Lee et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500
3. T.J. Lynch, D.W. Bell, and R. Sordella et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139
4. M.G. Kris, B.E. Johnson, and D.J. Kwiatkowski et al. Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: the NCI's Lung Cancer Mutation Consortium (LCMC) J Clin Oncol 29 2011 CRA7506
5. L. Ding, G. Getz, and D.A. Wheeler et al. Somatic mutations affect key pathways in lung adenocarcinoma Nature 455 2008 1069 1075
6. J.L. Marks, S. Broderick, and Q. Zhou et al. Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma J Thorac Oncol 3 2008 111 116
7. S.P. D'Angelo, Y.Y. Janjigian, and N. Ahye et al. Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib J Thorac Oncol 7 2012 1815 1822
8. S.P. D'Angelo, B. Park, and C.G. Azzoli et al. Reflex testing of resected stage I through III lung adenocarcinomas for EGFR and KRAS mutation: report on initial experience and clinical utility at a single center J Thorac Cardiovasc Surg 141 2011 476 480
9. X. Tang, H. Shigematsu, and B.N. Bekele et al. EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients Cancer Res 65 2005 7568 7572
10. F.B. Thunnissen, C. Prinsen, and B. Hol et al. Smoking history and lung carcinoma: KRAS mutation is an early hit in lung adenocarcinoma development Lung Cancer 75 2012 156 160
11. A. Youn, and R. Simon Estimating the order of mutations during tumorigenesis from tumor genome sequencing data Bioinformatics 28 2012 1555 1561
12. M.S. Tsao, A. Sakurada, and K. Ding et al. Prognostic and predictive value of epidermal growth factor receptor tyrosine kinase domain mutation status and gene copy number for adjuvant chemotherapy in non-small cell lung cancer J Thorac Oncol 6 2011 139 147
13. F.A. Shepherd, C. Domerg, and P. Hainaut et al. Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy J Clin Oncol 31 2013 2173 2181
14. T. Kosaka, Y. Yatabe, and R. Onozato et al. Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma J Thorac Oncol 4 2009 22 29
15. C. Mascaux, S. Ekman, and C. Dooms et al. Individualized therapy in the adjuvant setting for non-small cell lung cancer (NSCLC) Curr Respir Care Rep 2 2013 1 9
16. M. Bradic, J. Costa, and I.M. Chelo Genotyping with Sequenom Methods Mol Biol 772 2011 193 210
17. J. Leushner, and N.H. Chiu Automated mass spectrometry: a revolutionary technology for clinical diagnostics Mol Diagn 5 2000 341 348
18. R.K. Thomas, A.C. Baker, and R.M. Debiasi et al. High-throughput oncogene mutation profiling in human cancer Nat Genet 39 2007 347 351
19. C. Mascaux, N. Iannino, and B. Martin et al. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis Br J Cancer 92 2005 131 139
20. J.E. Chaft, M.E. Arcila, and P.K. Paik et al. Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling Mol Cancer Ther 11 2012 485 491
21. S.A. Ahrendt, P.A. Decker, and E.A. Alawi et al. Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung Cancer 92 2001 1525 1530
22. G.J. Riely, M.G. Kris, and D. Rosenbaum et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma Clin Cancer Res 14 2008 5731 5734
23. P. Hainaut, and G.P. Pfeifer Patterns of p53 G - >T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke Carcinogenesis 22 2001 367 374
24. H. Suzuki, T. Takahashi, and T. Kuroishi et al. p53 mutations in non-small cell lung cancer in Japan: association between mutations and smoking Cancer Res 52 1992 734 736
25. International Agency for Research on Cancer. IARC TP53 database. Available at: http://p53.iarc.fr/TP53SomaticMutations.aspx. Accessed: November 2013.
26. N. Rekhtman, P.K. Paik, and M.E. Arcila et al. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations Clin Cancer Res 18 2012 1167 1176
27. I.Y. Tam, L.P. Chung, and W.S. Suen et al. Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features Clin Cancer Res 12 2006 1647 1653
28. S.H. Park, S.Y. Ha, and J.I. Lee et al. Epidermal growth factor receptor mutations and the clinical outcome in male smokers with squamous cell carcinoma of lung J Korean Med Sci 24 2009 448 452
29. Y. Miyamae, K. Shimizu, and J. Hirato et al. Significance of epidermal growth factor receptor gene mutations in squamous cell lung carcinoma Oncol Rep 25 2011 921 928
30. N. Rekhtman, L.J. Tafe, and J.E. Chaft et al. Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma Mod Pathol 26 2013 511 522
31. P. Sardari Nia, J. Weyler, and C. Colpaert et al. Prognostic value of smoking status in operated non-small cell lung cancer Lung Cancer 47 2005 351 359
32. R.A. Meguid, C.M. Hooker, and J. Harris et al. Long-term survival outcomes by smoking status in surgical and nonsurgical patients with non-small cell lung cancer: comparing never smokers and current smokers Chest 138 2010 500 509
33. F. Le Calvez, A. Mukeria, and J.D. Hunt et al. TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers Cancer Res 65 2005 5076 5083
34. A. Parsons, A. Daley, and R. Begh et al. Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis BMJ 340 2010 b5569